IDYA
Price
$33.09
Change
-$1.14 (-3.33%)
Updated
Feb 4, 02:50 PM (EDT)
Capitalization
3B
55 days until earnings call
Intraday BUY SELL Signals
RCUS
Price
$20.83
Change
-$1.13 (-5.15%)
Updated
Feb 4, 03:14 PM (EDT)
Capitalization
2.72B
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs RCUS

Header iconIDYA vs RCUS Comparison
Open Charts IDYA vs RCUSBanner chart's image
IDEAYA Biosciences
Price$33.09
Change-$1.14 (-3.33%)
Volume$334
Capitalization3B
Arcus Biosciences
Price$20.83
Change-$1.13 (-5.15%)
Volume$1.3K
Capitalization2.72B
IDYA vs RCUS Comparison Chart in %
View a ticker or compare two or three
VS
IDYA vs. RCUS commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and RCUS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (IDYA: $34.23 vs. RCUS: $21.96)
Brand notoriety: IDYA and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 69% vs. RCUS: 39%
Market capitalization -- IDYA: $3B vs. RCUS: $2.72B
IDYA [@Biotechnology] is valued at $3B. RCUS’s [@Biotechnology] market capitalization is $2.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while RCUS’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 6 bearish.
  • RCUS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -1.47% price change this week, while RCUS (@Biotechnology) price change was -4.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

RCUS is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($3B) has a higher market cap than RCUS($2.72B). IDYA YTD gains are higher at: -0.984 vs. RCUS (-7.847). IDYA has higher annual earnings (EBITDA): -204.84M vs. RCUS (-323M). RCUS has more cash in the bank: 831M vs. IDYA (787M). IDYA has less debt than RCUS: IDYA (27.2M) vs RCUS (111M). RCUS has higher revenues than IDYA: RCUS (240M) vs IDYA (215M).
IDYARCUSIDYA / RCUS
Capitalization3B2.72B110%
EBITDA-204.84M-323M63%
Gain YTD-0.984-7.84713%
P/E RatioN/AN/A-
Revenue215M240M90%
Total Cash787M831M95%
Total Debt27.2M111M25%
FUNDAMENTALS RATINGS
IDYA vs RCUS: Fundamental Ratings
IDYA
RCUS
OUTLOOK RATING
1..100
679
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
67
Overvalued
PROFIT vs RISK RATING
1..100
63100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
4539
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (28) in the null industry is somewhat better than the same rating for RCUS (67) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than RCUS’s over the last 12 months.

IDYA's Profit vs Risk Rating (63) in the null industry is somewhat better than the same rating for RCUS (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than RCUS’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as RCUS (98) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as IDYA (45) in the null industry. This means that RCUS’s stock grew similarly to IDYA’s over the last 12 months.

RCUS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that RCUS’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYARCUS
RSI
ODDS (%)
Bearish Trend 2 days ago
64%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
75%
Bearish Trend 27 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
RCUS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGRCX108.46-1.08
-0.99%
Janus Henderson Enterprise C
IIRLX47.97-0.48
-0.99%
Voya Russell Large Cap Index Port I
MNVRX29.31-0.37
-1.25%
Madison Large Cap R6
ICTEX16.24-0.21
-1.28%
ICON Health and Information Tech Instl
JSGRX28.75-0.50
-1.71%
JHancock U.S. Growth R2

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.50%
NUVL - IDYA
59%
Loosely correlated
+2.12%
OCUL - IDYA
57%
Loosely correlated
-6.99%
XENE - IDYA
56%
Loosely correlated
+1.62%
XNCR - IDYA
55%
Loosely correlated
-0.99%
BEAM - IDYA
54%
Loosely correlated
-0.11%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+1.39%
XNCR - RCUS
51%
Loosely correlated
-0.99%
RLAY - RCUS
50%
Loosely correlated
+6.38%
VIR - RCUS
49%
Loosely correlated
-0.39%
IDYA - RCUS
48%
Loosely correlated
+0.50%
TRDA - RCUS
48%
Loosely correlated
-0.51%
More